文献速递心力衰竭与心肌病心律失常

RBM20截短变异与人类心肌病

RBM20 Truncating Variants and Human Cardiomyopathy.
PubMed 文献 · JAMA Cardiol · 2026-01-01

本研究通过UK Biobank、All of Us及国际DCM队列评估RBM20截短变异(RBM20tv)在致心律失常性DCM中的作用。RBM20变异的病因分数为0.53(95%CI 0.32-0.67;P<.001)。在基因组优先队列中,RBM20变异携带者终生心肌病、心衰或主要室性心律失常诊断发生率低于TTNtv携带者(HR 0.55;95%CI 0.36-0.84;P<.001)。RBM20tv合并DCM患者较P/LP RBM20合并DCM患者发病年龄更晚、家族史更少,但年龄性别校正后事件无显著差异。

要点

  • RBM20变异对致心律失常性DCM的病因分数为0.53(95%CI 0.32-0.67)。
  • RBM20变异携带者终生心肌病/心衰/室性心律失常风险低于TTNtv携带者(HR 0.55)。
  • RBM20tv合并DCM患者发病年龄晚于P/LP RBM20合并DCM患者(53岁 vs 34岁)。

核心结论

  • RBM20变异参与致心律失常性DCM表型,但终生疾病外显率低于TTNtv,单独致病严重程度轻于P/LP RBM20变异。
  • 在DCM患者及家系中应考虑RBM20tv与其他损害性变异的叠加交互作用。

研究设计与样本

  • 队列研究,纳入UK Biobank中4249名参与者(44%男性,平均年龄56岁,SD 8.2),评估RBM20tv、RBM20同义变异和TTNtv。
  • 国际RBM20注册队列179例患者(58.6%男性,平均年龄43.8岁,SD 19.1),回顾性收集DCM且携带RBM20变异患者数据。
  • All of Us生物库验证队列7002名参与者(62.0%男性,平均年龄52.7岁,SD 16.7)。

主要发现

  • RBM20变异在致心律失常性DCM中的病因分数为0.53(95%CI 0.32-0.67;P<.001)。
  • 基因组优先生物库中,RBM20变异携带者终生心肌病、心衰或主要室性心律失常诊断发生率低于TTNtv携带者(HR 0.55;95%CI 0.36-0.84;P<.001)。
  • RBM20tv合并DCM患者就诊年龄晚于P/LP RBM20合并DCM患者(平均53岁[SD 10] vs 34岁[SD 18];P<.001)。
  • RBM20tv合并DCM患者心脏骤停家族史比例低于P/LP RBM20合并DCM患者(2/10 [20%] vs 11/17 [65%];P=.046)。
  • RBM20tv合并DCM患者心肌病家族史比例低于P/LP RBM20合并DCM患者(2/10 [20%] vs 14/18 [78%];P<.001)。

关键数值与推荐

  • RBM20tv合并DCM与P/LP RBM20合并DCM患者年龄性别校正后主要心衰或心律失常事件无显著差异。
  • RBM20tv合并DCM患者性别校正终生风险降低(HR 0.13;95%CI 0.03-0.56;P=.01)。

临床怎么用

  • 对DCM患者进行RBM20变异解读时,应区分截短变异与P/LP错义变异,并评估与其他损害性变异的叠加效应。
  • RBM20tv携带者终生外显率低于TTNtv,遗传咨询时需考虑其发病年龄较晚及家族史较少的特点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Genetic diagnosis has become increasingly important to guide clinical decision-making for patients with dilated cardiomyopathy (DCM). Pathogenic or likely pathogenic (P/LP) missense variants in the gene RBM20 cause a highly penetrant arrhythmogenic DCM, but the role of RBM20 truncating variants (RBM20tvs) is unclear. OBJECTIVE: To assess the contribution of RBM20 variants to arrhythmogenic DCM. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, participants in the genome-first UK Biobank (UKB) and All of Us populations were evaluated to assess the etiologic fraction, natural history and penetrance of RBM20 variants. Retrospective data were collected from an international cohort of patients with DCM and RBM20 variants identified at centers of excellence for genetic heart disease and compared based on time to event. Study dates are not disclosed because the institutional review board did not authorize the sharing of this information. EXPOSURES: RBM20 variants were compared to known P/LP variants and variants of uncertain significance in RBM20 as well as titin truncating variants (TTNtvs). MAIN OUTCOMES AND MEASURES: Major ventricular arrhythmias, end-stage heart failure, and heart failure hospitalization as measured by medical record review (retrospective cohort) and diagnostic codes (UKB). RESULTS: Two main cohorts were studied for this project. In UK Biobank, a cohort of participants with RBM20tvs, RBM20 synonymous variants, and TTNtvs was studied. Of these 4249 participants, 1869 (44%) were male. The mean (SD) age at enrollment was 56 (8.2) years. In the RBM20 registry, of 179 patients, 105 (58.6%) were male, and the mean (SD) age at enrollment was 43.8 (19.1) years. A validation cohort from the All of Us biobank was also used. This consisted of 7002 participants, 4342 of whom (62.0%) were male, and the mean (SD) age was 52.7 (16.7) years. The etiologic fraction of RBM20 variants in arrhythmogenic DCM was 0.53 (95% CI, 0.32-0.67; P < .001). In genome-first biobanks, lifetime incidence of cardiomyopathy, heart failure, or major ventricular arrhythmia diagnosis was lower in participants with RBM20 variants than in those with TTNtvs (hazard ratio, 0.55; 95% CI, 0.36-0.84; P < .001). Patients with RBM20tvs and DCM presented to referral centers later in life than those with P/LP RBM20 and DCM (mean [SD], 53 [10] vs 34 [18] years; P < .001) and were less likely to have a family history of sudden cardiac arrest (2 of 10 [20%] vs 11 of 17 [65%]; P = .046) or cardiomyopathy (2 of 10 [20%] vs 14 of 18 [78%]; P < .001). There was no significant difference in age- and sex-adjusted incident major heart failure or arrhythmia events between patients with RBM20tv and DCM or those with P/LP RBM20 and DCM, though sex-adjusted lifetime hazard was reduced in those with RBM20tv and DCM (hazard ratio, 0.13; 95% CI, 0.03-0.56; P = .01). CONCLUSIONS AND RELEVANCE: This study found that RBM20 variants contributed to arrhythmogenic DCM phenotypes but conferred reduced lifetime disease penetrance compared to TTNtvs and milder disease severity alone than P/LP RBM20 variants. Their potential for additive interactions with other damaging variants should be considered in patients with DCM and their families.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Floyd BJ, Njoroge JN, Krysov VA, et al. RBM20 Truncating Variants and Human Cardiomyopathy. JAMA Cardiol. 2026. PMID: 41949880. doi:10.1001/jamacardio.2026.0401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。